FINWIRES · TerminalLIVE
FINWIRES

EU Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer

By

EU approves AstraZeneca and Daiichi Sankyo's (TYO:4568) Datroway as first-line monotherapy for metastatic triple-negative breast cancer patients ineligible for PD-1/PD-L1 inhibitors, according to a statement on Friday.

The decision is based on the TROPION-Breast02 Phase III trial, which demonstrated a 5-month improvement in median overall survival and a 43% reduction in the risk of disease progression or death compared to chemotherapy.

This approval makes Datroway the only TROP2-directed antibody drug conjugate in the EU to show an overall survival benefit in this first-line setting, the statement read.

The therapy, which was previously approved in the US in May, is now recommended in ESMO Clinical Practice Guidelines as a Category IA treatment option for eligible patients.

Related Articles

Asia

ASE Technology's Q2 Profit Shoots Up as Revenue Rises 27%

ASE Technology's (TPE:3711) attributable profit surged to NT$21.1 billion in the second quarter from NT$7.52 billion a year earlier.Diluted earnings per share rose to NT$4.61 from NT$1.70 a year earlier.Revenue climbed 27% year over year to NT$191.1 billion due to higher semiconductor assembly, testing and electronic manufacturing services sales. On a sequential basis, revenue increased 10%.Gross margin improved to 21% from 20% in the first quarter, while operating margin rose to 11% from 10%, it said.

TPE:3711
Asia

Fitch Affirms Sinochem at A, Stable Outlook

Fitch Ratings affirmed Sinochem International's (SHA:600500) long-term foreign-currency issuer default rating and senior unsecured rating at A-, with a stable outlook, the ratings firm said Thursday.The new ratings reflected the state-owned firm's parent, Sinochem Holdings Corporation, which was rated with "Low" legal, "Medium" strategic, and "High" operational incentives to support Sinochem.The ratings firm decided to withdraw the ratings due to commercial reasons.

SHA:600500
Asia

Cinda Securities H1 Profit Up 7%, Revenue Rises 20%

Cinda Securities (SHA:601059) posted first-half attributable net profit of 1.10 billion yuan, up 7.2% from 1.02 billion yuan the previous year.Earnings per share were unchanged at 0.30 yuan, according to a filing with the Shanghai bourseOperating revenue climbed 20% year over year to 2.44 billion yuan from 2.04 billion yuan.Shares of the brokerage were down 1% in recent trade.

SHA:601059